[1]
|
Perera, N.D. and Mansfield, A.S. (2022) The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma. Current Oncology Reports, 24, 1413-1423. https://doi.org/10.1007/s11912-022-01302-3
|
[2]
|
Nakajima, E.C., Vellanki, P.J., Larkins, E., Chatterjee, S., Mishra-Kalyani, P.S., Bi, Y., Qosa, H., Liu, J., Zhao, H., Biable, M., Hotaki, L.T., Shen, Y.L., Pazdur, R., Beaver, J.A., Singh, H. and Donoghue, M. (2022) FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma. Clinical Cancer Research, 28, 446-451. https://doi.org/10.1158/1078-0432.CCR-21-1466
|
[3]
|
Sun, H.H., Vaynblat, A. and Pass, H.I. (2017) Diagnosis and Prognosis-Review of Biomarkers for Mesothelioma. Annals of Translational Medicine, 5, Article 244. https://doi.org/10.21037/atm.2017.06.60
|
[4]
|
Schillebeeckx, E., van Meerbeeck, J.P. and Lamote, K. (2021) Clinical Utility of Diagnostic Biomarkers in Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis. European Respiratory Review, 30, Article 210057. https://doi.org/10.1183/16000617.0057-2021
|
[5]
|
Cavallari, I., Urso, L., Sharova, E., Pasello, G. and Ciminale, V. (2019) Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives. Frontiers in Oncology, 9, Article 740. https://doi.org/10.3389/fonc.2019.00740
|
[6]
|
Pass, H.I., Alimi, M., Carbone, M., Yang, H. and Goparaju, C.M. Mesothelioma Biomarkers: Discovery in Search of Validation. Thoracic Surgery Clinics, 30, 395-423. https://doi.org/10.1016/j.thorsurg.2020.08.001
|
[7]
|
杨晓川, 张强. 影像学检查在恶性胸膜间皮瘤中的应用[J]. 影像研究与医学应用, 2019, 3(1): 1-3.
|
[8]
|
Gill, R.R., Patz, S., Muradyan, I. and Seethamraju, R.T. (20150 Novel MR Imaging Applications for Pleural Evaluation. Magnetic Resonance Imaging Clinics of North America, 23, 179-195. https://doi.org/10.1016/j.mric.2015.01.006
|
[9]
|
Dubreuil, J., Giammarile, F., Rousset, P., Rubello, D., Bakrin, N., Passot, G., Isaac, S., Glehen, O. and Skanjeti, A. (2017) The Role of 18F-FDG-PET/Cect in Peritoneal Mesothelioma. Nuclear Medicine Communications, 38, 312-318. https://doi.org/10.1097/MNM.0000000000000649
|
[10]
|
Barbieri, P.G., Consonni, D. and Schneider, M. (2022) Accuracy of Pleural Biopsy for the Diagnosis of Histologic Subtype of Malignant Pleural Mesothelioma: Necropsy-Based Study of 134 Cases. Tumori Journal, 108, 26-32. https://doi.org/10.1177/0300891620988354
|
[11]
|
Butchart, E.G., Ashcroft, T., Barnsley, W.C. and Holden, M.P. (1976) Pleuropneumonectomy in the Management of Diffuse Malignant Mesothelioma of the Pleura. Experience with 29 Patients. Thorax, 31, 15-24. https://doi.org/10.1136/thx.31.1.15
|
[12]
|
Sugarbaker, D.J., Strauss, G.M., Lynch, T.J., Richards, W., Mentzer, S.J., Lee, T.H., Corson, J.M. and Antman, K.H. (1993) Node Status Has Prognostic Significance in the Multimodality Therapy of Diffuse, Malignant Mesothelioma. Journal of Clinical Oncology, 11, 1172-1178. https://doi.org/10.1200/JCO.1993.11.6.1172
|
[13]
|
Rusch, V.W., Chansky, K., Kindler, H.L., Nowak, A.K., Pass, H.I., Rice, D.C., Shemanski, L., Galateau-Sallé, F., Mccaughan, B.C., Nakano, T., Ruffini, E., van Meerbeeck, J.P. and Yoshimura, M. (2016) The IASLC Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions. The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. Journal of Thoracic Oncology, 11, 2112-2119.
|
[14]
|
丁婧, 林桐榆. 恶性胸膜间皮瘤治疗展望[J]. 肿瘤预防与治疗, 2023, 36(4): 271-279.
|
[15]
|
Yorke, E.D., Jackson, A., Kuo, L.C., Ojo, A., Panchoo, K., Adusumilli, P., Zauderer, M.G., Rusch, V.W., Shepherd, A. and Rimner, A. (2017) Heart Dosimetry Is Correlated with Risk of Radiation Pneumonitis after Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. International Journal of Radiation Oncology, Biology, Physics, 99, 61-69. https://doi.org/10.1016/j.ijrobp.2017.04.025
|
[16]
|
Taioli, E., Wolf, A.S. and Flores, R.M. (2015) Meta-Analysis of Survival after Pleurectomy Decortication versus Extrapleural Pneumonectomy in Mesothelioma. The Annals of Thoracic Surgery, 99, 472-480. https://doi.org/10.1016/j.athoracsur.2014.09.056
|
[17]
|
Popat, S., Baas, P., Faivre-Finn, C., Girard, N., Nicholson, A.G., Nowak, A.K., Opitz, I., Scherpereel, A. and Reck, M. (2022) Malignant Pleural Mesothelioma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 33, 129-142. https://doi.org/10.1016/j.annonc.2021.11.005
|
[18]
|
Zalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., Monnet, I., Gounant, V., Rivière, F., Janicot, H., Gervais, R., Locher, C., Milleron, B., Tran, Q., Lebitasy, M.P., Morin, F., Creveuil, C., Parienti, J.J. and Scherpereel, A. (2016) French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for Newly Diagnosed Pleural Mesothelioma in The Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A Randomised, Controlled, Open-Label, Phase 3 Trial. The Lancet, 387, 1405-1414. https://doi.org/10.1016/S0140-6736(15)01238-6
|
[19]
|
唐善卫, 唐桂旺, 束余声. 恶性胸膜间皮瘤治疗的研究进展[J]. 癌症进展, 2019, 17(11): 1245-1250.
|
[20]
|
Stahel, R.A., Riesterer, O., Xyrafas, A., Opitz, I., Beyeler, M., Ochsenbein, A., Früh, M., Cathomas, R., Nackaerts, K., Peters, S., Mamot, C., Zippelius, A., Mordasini, C., Caspar, C.B., Eckhardt, K., Schmid, R.A., Aebersold, D.M., Gautschi, O., Nagel, W., Töpfer, M., Krayenbuehl, J., Ribi, K., Ciernik, I.F. and Weder, W. (2015) Neoadjuvant Chemotherapy and Extrapleural Pneumonectomy of Malignant Pleural Mesothelioma with or Without Hemithoracic Radiotherapy (SAKK 17/04): A Randomized, International, Multicentre Phase 2 Trial. The Lancet Oncology, 16, 1651-1658. https://doi.org/10.1016/S1470-2045(15)00208-9
|
[21]
|
Khan, A.M.H., Anwer, S.H., Sayed, S., Mansha, M.A., Kamran, Y.B., Khursheed, A., Haroon, F., Soomro, N.H., Idrees, R. and Abbasi, A.N. (2024) Comprehensive Clinical Overview of Malignant Pleural Mesothelioma. Respiratory Medicine, 222, Article 107511. https://doi.org/10.1016/j.rmed.2023.107511
|
[22]
|
Barsky A.R., Cengel K.A., Katz S.I., Sterman D.H. and Simone Ⅱ, C.B. (2019) First-Ever Abscopal Effect after Palliative Radiotherapy and Immuno-Gene Therapy for Malignant Pleural Mesothelioma. Cureus, 11, E4102. https://doi.org/10.7759/cureus.4102
|
[23]
|
Rimner, A., Hu, C., Zauderer, M., et al. (2020) A Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy with or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM) (NRG-LU006). International Journal of Radiation Oncology, Biology, Physics, 108, E928-E929. https://doi.org/10.1016/j.ijrobp.2020.07.583
|
[24]
|
Bayman, N., Appel, W., Ashcroft, L., Baldwin, D.R., Bates, A., Darlison, L., Edwards, J.G., Ezhil, V., Gilligan, D., Hatton, M., Jegannathen, A., Mansy, T., Peake, M.D., Pemberton, L., Rintoul, R.C., Snee, M., Ryder, W.D., Taylor, P. and Faivre-Finn, C. (2019) Prophylactic Irradiation of Tracts in Patients with Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial. Journal of Clinical Oncology, 37, 1200-1208. https://doi.org/10.1200/JCO.18.01678
|
[25]
|
Borea, F., Franczak, M.A., Garcia, M., Perrino, M., Cordua, N., Smolenski, R.T., Peters, G.J., Dziadziuszko, R., Santoro, A., Zucali, P.A. and Giovannetti, E. (2023) Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage? International Journal of Molecular Sciences, 24, Article 9165. https://doi.org/10.3390/ijms24119165
|
[26]
|
Nowak, A.K., Brosseau, S., Cook, A. and Zalcman, G. (2020) Antiangiogeneic Strategies in Mesothelioma. Frontiers in Oncology, 10, Article 126. https://doi.org/10.3389/fonc.2020.00126
|
[27]
|
Tsao, A.S., Harun, N., Lee, J.J., Heymach, J., Pisters, K., Hong, W.K., Fujimoto, J. and Wistuba, I. (2014) Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma. Clinical Lung Cancer, 15, 197-201. https://doi.org/10.1016/j.cllc.2013.12.008
|
[28]
|
Onen, H.I., Yilmaz, A., Alp, E., Celik, A., Demiroz, S.M., Konac, E., Kurul, I.C. and Menevse, E.S. (2015) EF24 and RAD001 Potentiates the Anticancer Effect of Platinum-Based Agents in Human Malignant Pleural Mesothelioma (MSTO-211H) Cells and Protects Nonmalignant Mesothelial (MET-5A) Cells. Human & Experimental Toxicology, 34, 117-126. https://doi.org/10.1177/0960327114542965
|
[29]
|
Baas, P., Scherpereel, A., Nowak, A.K., Fujimoto, N., Peters, S., Tsao, A.S., Mansfield, A.S., Popat, S., Jahan, T., Antonia, S., Oulkhouir, Y., Bautista, Y., Cornelissen, R., Greillier, L., Grossi, F., Kowalski, D., Rodríguez-Cid, J., Aanur, P., Oukessou, A., Baudelet, C. and Zalcman, G. (2021) First-Line Nivolumab Plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (Checkmate 743): A Multicentre, Randomized, Open-Label, Phase 3 Trial. The Lancet, 397, 375-386. https://doi.org/10.1016/S0140-6736(20)32714-8
|
[30]
|
Sterman, D.H., Alley, E., Stevenson, J.P., Friedberg, J., Metzger, S., Recio, A., Moon, E.K., Haas, A.R., Vachani, A., Katz, S.I., Sun, J., Heitjan, D.F., Hwang, W.T., Litzky, L., Yearley, J.H., Tan, K.S., Papasavvas, E., Kennedy, P., Montaner, L.J., Cengel, K.A., Simone Ⅱ, C.B., Culligan, M., Langer, C.J. and Albelda, S.M. (2016) Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNΑ Combined with Chemotherapy. Clinical Cancer Research, 22, 3791-3800. https://doi.org/10.1158/1078-0432.CCR-15-2133
|